Drugs / FRM-0334
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02149160 | Oct 2014 → Aug 2016 | GRN-related frontotemporal lobar degeneration with Tdp43 inclusions | FORUM Pharmaceuticals Inc | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FRM-0334 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02149160 ↗ |
| Action | Inhibit | “Histone Deacetylase Inhibitor FRM-0334” NCT02149160 ↗ |
| Modality | Small molecule | “Histone Deacetylase Inhibitor FRM-0334” NCT02149160 ↗ |
| Route | Oral | “OBJECTIVE: To characterize the safety, tolerability, plasma pharmacokinetics, and pharmacodynamic effects of oral FRM-0334” PMID 34559230 ↗ Sep 2021 |